Compare Abbott Laboratories (ABT) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Palantir Technologies Inc — how do they compare? Abbott Laboratories trades at $109.55 (market cap $187.95B), while Palantir Technologies Inc trades at $172.58 (market cap $421.09B). The key difference: Palantir Technologies Inc is far larger — about 2.2× Abbott Laboratories's market cap, and Abbott Laboratories pays a 2.32% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| ABT | PLTR | |
|---|---|---|
Market Cap | $187.95B | $421.09B |
Sector | Health | Technology |
52-Week High | $136.62 | $207.18 |
52-Week Low | $82.57 | $107.27 |
Enterprise Value | $214.96B | $411.89B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Palantir (PLTR) trades at $172.01, up 10.32% in 24 hours and near its 52-week high, with bullish technical signals from moving averages. The company reported strong Q2 2026 earnings, beating estimates with 93% revenue growth and a 55% net income margin, while raising full-year guidance. Analyst consensus is a Buy with a $213.44 price target, reflecting optimism around AI-driven commercial expansion.
Outlook remains positive due to accelerating revenue and robust profitability, but high valuation multiples (P/E of 147.02) pose a risk if growth slows. Key opportunities include the $13.1 billion deal backlog and U.S. commercial segment growth, while risks involve competition and execution challenges in sustaining AI adoption momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
